ABBV-453
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
What's the purpose of the trial?
The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM.
Accepting patients
Participating Centers
There are 12 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- ABBV-453 is an investigational drug being developed for the treatment of relapsed/refractory multiple myeloma. It is a first-in-human, BCL-2 inhibitor.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.